Lifetree Clinical Research LC

1. Eli Lilly and Company $110,286 9 payments
2. Amgen Inc. $32,748 1 payment
3. Sunovion Pharmaceuticals Inc. $13,801 2 payments
4. Takeda Pharmaceuticals U.S.A., Inc. $7,530 3 payments

1. A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3437943 in Patients With Type 2 Diabetes Mellitus $39,645 3 payments
2. A Phase 1 Randomized Placebo-Controlled Dose-Escalation Study to Evaluate the Safety Tolerability and PK of Ly3541105 Following Single Doses in Healthy/Overweight Participants and Multiple Doses in Overweight Participants $37,183 1 payment
3. A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and PK of Ly3541105 Following Single Doses in Healthy/Overweight Participants and Multiple Doses in Overweight Participants $32,967 2 payments
4. Phase 2 Episodic Migraine Prophylaxis EMP $32,748 1 payment
5. Pediatric Open-Label Extension Study $13,801 2 payments
6. Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD $7,530 3 payments
7. A Phase 1B Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced Or Metastatic Soft Tissue Sarcoma $241 1 payment
8. A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of Ly3002813 in Patients With Mild Cognitive Impairment Due to Alzheimers Disease Or Mild to Moderate Alzheimers Disease Or Mild to Moderate Alzheimers Disease $150 1 payment
9. A Study of Ly3372993 in Healthy Participants and Participants With Alzheimer's Disease (Ad) $100 1 payment

1. Other $7,530 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.